【摘要】 目的　探讨不同化疗方案对治疗非小细胞肺癌所产生的经济效果。方法　根据不同治疗方案, 选择96例非小细胞肺癌患者, 分成4组, 分别为NP组(诺维本、顺铂)、MVP组(丝裂霉素、西艾克、顺铂)、TP组(紫杉醇、顺铂)、GP组(健择、顺铂), 运用药物经济学中成本-效果分析方法进行回顾性分析评价。结果　4种方案的平均成本分别为7 368. 4元、2 103. 6元、22 422 4元、18 703 .2元; 有效率分别为51 .3%、48 .1%; 52 .9%、53. 8%。结论　从药物经济学的观点分析, MVP方案是治疗非小细胞肺癌的最佳方案。更多还原

【Abstract】 Objective To evaluate the economical effe cts of four different chemotherapy regimens in the treatment of non-small cell l ung cancer (NSCLC). Methods 96 cases of NSCLC were randomly divided into four g roups: NP group (NVB+DDP), MVP group (MMC+VDS+DDP), TP group (TAX+DDP) and GP gr oup (GEM+DDP). Then using cost-effectiveness analysis of pharmacy-economics perf ormed retrospective analysis and evaluation for these programs. Results The average cost of each group was 7 368.4 yuan,2 103.6 yuan,22 422.4 yuan and 18 703.2 yuan(RMB) respectively. And the effecti ve rate was 51.3%, 48.1%,52.9% and 53.8% respectively. Conclusion MVP chemotherapy regimen is the optimal scheme f or NSCLC in the four programs according to these pharmacy-economic evaluations.更多还原